• Propanc outlined PRP, a once-weekly IV combination of trypsinogen and chymotrypsinogen, as a differentiation-based approach for RAS-driven cancers.
• Preclinical PDAC studies cited >90% mean tumor growth inhibition in orthotopic and PDX models, marked metastasis reduction, median survival >2.5x (p < 0.001).
• Program positioned as non-cytotoxic, aimed at reversing EMT and reducing cancer stem-cell traits linked to recurrence and treatment resistance.
• Development plan targets a Phase 1b first-in-human study in up to 40-45 advanced solid-tumor patients, with a clinical trial filing planned for Q4.
• FDA Orphan Drug Designation for pancreatic cancer; prior compassionate-use experience cited prolonged survival signals without severe treatment-related adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.